Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia

References

• Mollenhauer B, Weintraub D. The depressed brain in Parkinson’s disease: implications for an inflammatory biomarker. Proc Natl Acad Sci U S A. 2017;114(12):3004–3005. doi:10.1073/pnas.170073711428283656
   PubMed Web of Science ®Google Scholar
• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535. doi:10.1016/S1474-4422(06)70471-916713924
   PubMed Web of Science ®Google Scholar
• Mehanna R, Moore S, Hou JG, Sarwar AI, Lai EC. Comparing clinical features of young onset, middle onset and late-onset Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(5):530–534. doi:10.1016/j.parkreldis.2014.02.01324631501
   PubMed Web of Science ®Google Scholar
• Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. PT. 2014;39(9):638–645.
   PubMedGoogle Scholar
• Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet. 2011;377(9783):2093–2102. doi:10.1016/S0140-6736(11)60512-621652063
   PubMed Web of Science ®Google Scholar
• Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485–515. doi:10.1038/nrd.2016.2826939910
   PubMed Web of Science ®Google Scholar
• Bogerts B, Häntsch J, Herzer M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. BiolPsychiatry. 1983;18(9):951–969.
   Google Scholar
• Kinoshita K, Tada Y, Muroi Y. Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning. Life Sci. 2015;137:28–36. doi:10.1016/j.lfs.2015.07.01726209139
   PubMed Web of Science ®Google Scholar
• Grace A. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. 2012;62(3):1342–1348. doi:10.1016/j.neuropharm.2011.05.01121621548
   PubMed Web of Science ®Google Scholar
• Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008;4(4):743–757.19043519
   PubMedGoogle Scholar
• Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present, and future. Curr Top Med Chem. 2016;16(29):3385–3403.27291902
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–128. doi:10.1016/j.ncl.2010.10.00221172575
   PubMed Web of Science ®Google Scholar
• Hariprasad G, Hariprasad R, Kumar L, Srinivasan A, Kola S, Kaushik A. Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. Biomarkers. 2013;18(6):532–541. doi:10.3109/1354750X.2013.82256123902290
   PubMed Web of Science ®Google Scholar
• Rukmangadachar LA, Makharia GK, Mishra A, et al. Proteome analysis of the macroscopically affected colonic mucosa of Crohn’s disease and intestinal tuberculosis. Sci Rep. 2016;6:23162. doi:10.1038/srep2316226988818
   PubMed Web of Science ®Google Scholar
• Sehrawat U, Pokhriyal R, Gupta AK, et al. Proteomic analysis of advanced ovarian cancer tissue to identify potential biomarkers of responders and nonresponders to first-line chemotherapy of carboplatin and paclitaxel. Biomark Cancer. 2016;16(8):43–56.
   Google Scholar
• Kataria J, Rukmangadachar LA, Hariprasad G, et al. Two-dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients. J Proteomics. 2011;74(10):2194–2203. doi:10.1016/j.jprot.2011.06.02021723968
   PubMed Web of Science ®Google Scholar
• Rukmangadachar LA, Kataria J, Hariprasad G, Samantaray JC, Srinivasan A. Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients. Clin Proteomics. 2011;8(1):4. doi:10.1186/1559-0275-8-221906353
   PubMedGoogle Scholar
• Manral P, Sharma P, Hariprasad G, Chandralekha TM, Srinivasan A. Can apolipoproteins and complement factors be biomarkers of Alzheimer’s disease? CurrAlzheimer Res. 2012;9(8):935–943.
   Google Scholar
• Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. ParkinsonismRelatDisord. 2014;20:S99–S103.
   Google Scholar
• Sabherwal S, English JA, Föcking M, Cagney G, Cotter DR. Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays. Expert Rev Proteomics. 2016;13(12):1141–1155. doi:10.1080/14789450.2016.125226227771981
   PubMed Web of Science ®Google Scholar
• Gupta AK, Rani K, Swarnkar S, et al. Evaluation of serum apolipoprotein E as a potential biomarker for pharmacological therapeutic efficacy monitoring in dopamine dictated disease spectrum of schizophrenia and Parkinson’s disease. J Cent NervSyst Dis. 2018;10:1179573518803585.
   Web of Science ®Google Scholar
• Gupta AK, Kumar GK, Rani K, et al. 2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine dictated states of Parkinson’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1031–1044. doi:10.2147/NDT.S19855931114209
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–630.3283935
   PubMed Web of Science ®Google Scholar
• Yu CE, Cudaback E, Foraker J, et al. Epigenetic signature and enhancer activity of the human APOE gene. Hum Mol Genet. 2013;22(24):5036–5047. doi:10.1093/hmg/ddt35423892237
   PubMed Web of Science ®Google Scholar
• Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40(1):1–6.9869645
   PubMed Web of Science ®Google Scholar
• Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Re Genomics Hum Genet. 2000;1:507–537. doi:10.1146/annurev.genom.1.1.507
   PubMed Web of Science ®Google Scholar
• Zerba KE, Ferrell RE, Sing CF. Complex adaptive systems and human health: the influence of common genotypes of the apolipoprotein E (ApoE) gene polymorphism and age on the relational order within a field of lipid metabolism traits. Hum Genet. 2000;107(5):466–475.11140944
   PubMed Web of Science ®Google Scholar
• Harhangi BS, de Rijk MC, Van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54(6):1272–1276. doi:10.1212/wnl.54.6.127210746597
   PubMed Web of Science ®Google Scholar
• Souza DR, de Godoy MR, Hotta J, et al. Association of apolipoprotein E polymorphism in late-onset Alzheimer’s disease and vascular dementia in Brazilians. Braz J Med Biol Res. 2003;36(7):919–923. doi:10.1590/s0100-879x200300070001312845379
   PubMed Web of Science ®Google Scholar
• Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, SNCA, and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405–1412. doi:10.1001/jamaneurol.2014.145525178429
   PubMed Web of Science ®Google Scholar
• Gibbons AS, Udawela M, Jeon WJ, Seo MS, Brooks L, Dean B. The neurobiology of APOE in schizophrenia and mood disorders. Front Biosci. 2011;16:962–979. doi:10.2741/3729
   Web of Science ®Google Scholar
• Chen X, de Silva HA, Pettenati MJ, et al. The human NACP/α-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics. 1995;26(2):425–427.7601479
   PubMed Web of Science ®Google Scholar
• Withers GS, George JM, Banker GA, Clayton DF. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res. 1997;99:87–94.9088569
   PubMedGoogle Scholar
• Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. α-synuclein-membrane interactions and lipid specificity. J Biol Chem. 2000;275(44):34328–34334. doi:10.1074/jbc.M00434520010915790
   PubMed Web of Science ®Google Scholar
• Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of α-synuclein. J Neurosci. 2004;24(30):6715–6723. doi:10.1523/JNEUROSCI.1594-04.200415282274
   PubMed Web of Science ®Google Scholar
• Xu L, Pu J. α-synuclein in Parkinson’s disease: from pathogenetic dysfunction to potential clinical application. Parkinsons Dis. 2016;2016:1720621.27610264
   PubMed Web of Science ®Google Scholar
• Olanow CW, Brundin P. Parkinson’s disease and alpha-synuclein: is Parkinson’s disease a prion-like disorder? Mov Disord. 2013;28(1):31–40. doi:10.1002/mds.2537323390095
   PubMed Web of Science ®Google Scholar
• Demirel ÖF, Cetin İ, Turan Ş, Sağlam T, Yıldız N, Duran A. Decreased expression of α-Synuclein, Nogo-A, and UCH-L1 in patients with schizophrenia: a preliminary serum study. Psychiatry Investig. 2017;14(3):344–349. doi:10.4306/pi.2017.14.3.344
   Web of Science ®Google Scholar
• Noori-Daloii MR, Kheirollahi M, Mahbod P, et al. Alpha- and beta-synucleins mRNA expression in lymphocytes of schizophrenia patients. Genet Test Mol Biomarkers. 2010;14(5):725–729. doi:10.1089/gtmb.2010.005020854101
   PubMed Web of Science ®Google Scholar
• Chou KL, Taylor JL, Patil PG. The MDS–UPDRS tracks motor and non– a motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord. 2013;19(11):966–969. doi:10.1016/j.parkreldis.2013.06.01023849499
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendation. Mov Disord. 2004;19:1020–1028. doi:10.1002/mds.2021315372591
   PubMed Web of Science ®Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Available from: https://apps.who.int/iris/handle/10665/37958. Accessed June 28, 2019.
   Google Scholar
• Ganapathiraju MK, Thahir M, Handen A, et al. Schizophrenia interactome with 504 novel protein-protein interactions. NPJ Schizophr. 2016;2:16012. doi:10.1038/npjschz.2016.1227336055
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432. doi:10.1093/bioinformatics/btq67521149340
   PubMed Web of Science ®Google Scholar
• Chatr-Aryamontri A, Ceol A, Palazzi LM, et al. MINT: the Molecular INTeraction database. Nucleic Acids Res. 2007;35:D572–D574. doi:10.1093/nar/gkl95017135203
   PubMed Web of Science ®Google Scholar
• Gao J, Ade AS, Tarcea VG, et al. Integrating and annotating the interactome using the MiMI plugin for Cytoscape. Bioinformatics. 2009;5(1):137–138. doi:10.1093/bioinformatics/btn501
   Web of Science ®Google Scholar
• Jensen LJ, Kuhn M, Stark M, et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37:D412–D416. doi:10.1093/nar/gkn76018940858
   PubMed Web of Science ®Google Scholar
• Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database-2009 update. Nucleic Acids Res. 2009;37(Database issue):D767–D772. doi:10.1093/nar/gkn89218988627
   PubMed Web of Science ®Google Scholar
• Calderone A, Castagnoli L, Cesareni G. Mentha: a resource for browsing integrated protein-interaction networks. Nat Methods. 2013;10(8):690–691. doi:10.1038/nmeth.256123900247
   PubMed Web of Science ®Google Scholar
• Rostovtseva TK, Gurnev PA, Protchenko O, et al. α-synuclein shows high-affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. J Biol Chem. 2015;290(30):18467–18477. doi:10.1074/jbc.M115.64174626055708
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang C, Cai Q, et al. Voltage-dependent anion channel involved in the α-synuclein-induced dopaminergic neuron toxicity in rats. Acta Biochim Biophys Sin. 2013;45(3):170–178. doi:10.1093/abbs/gms11423291291
   PubMedGoogle Scholar
• Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol. 2009;46(6):821–831. doi:10.1016/j.yjmcc.2009.02.02119265700
   PubMed Web of Science ®Google Scholar
• Beutner G, Rück A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. The implication for regulation of permeability transition by the kinases. Biochim Biophys Acta. 1998;1368(1):7–18.9459579
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis. 2007;12(5):835–840. doi:10.1007/s10495-006-0525-717136322
   PubMed Web of Science ®Google Scholar
• Schinzel AC, Takeuchi O, Huang Z, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA. 2005;102(34):12005–12010. doi:10.1073/pnas.050529410216103352
   PubMed Web of Science ®Google Scholar
• Gincel D, Shoshan-Barmatz V. Glutamate interacts with VDAC and modulates the opening of the mitochondrial permeability transition pore. J Bioenerg Biomembr. 2004;36(2):179–186.15224967
   PubMed Web of Science ®Google Scholar
• McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent α-synuclein protein interactions. Mol Cell Proteomics. 2008;7(11):2123–2137. doi:10.1074/mcp.M800116-MCP20018614564
   PubMed Web of Science ®Google Scholar
• Liani E, Eyal A, Avraham E, et al. Ubiquitylation of synphilin-1 and α-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson’s disease. Proc Natl Acad Sci. 2004;101(15):5500–5555. doi:10.1073/pnas.040108110115064394
   PubMed Web of Science ®Google Scholar
• Dashtipour K, Tafreshi A, Adler C, et al. Hypermethylation of synphilin-1, Α-synuclein-interacting protein (SNCAIP) gene in the cerebral cortex of patients with sporadic Parkinson’s disease. Brain Sci. 2017;7:7. doi:10.3390/brainsci7070074
   Web of Science ®Google Scholar
• Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ. GTPase activity and neuronal toxicity of Parkinson’s disease-associated LRRK2 is regulated by ArfGAP1. GTPase activity and neuronal toxicity of Parkinson’s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012;8(2):e1002526. doi:10.1371/journal.pgen.100252622363216
   PubMed Web of Science ®Google Scholar
• Wu J, Lou H, Alerte TN, et al. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience. 2012;07:288–297. doi:10.1016/j.neuroscience.2012.01.028
   Web of Science ®Google Scholar
• Hua G, Xiaolei L, Weiwei Y, et al. Protein phosphatase 2A is involved in the tyrosine hydroxylase phosphorylation regulated by α-synuclein. Neurochem Res. 2015;40(3):428–437. doi:10.1007/s11064-014-1477-x25567480
   PubMed Web of Science ®Google Scholar
• Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci. 2005;118(15):3523–3530. doi:10.1242/jcs.0248116030137
   PubMed Web of Science ®Google Scholar
• Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J. 2001;15(6):916–926. doi:10.1096/fj.00-0334com11292651
   PubMed Web of Science ®Google Scholar
• Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by α-synuclein. Neurosci Lett. 2003;340(3):189–192.12672538
   PubMed Web of Science ®Google Scholar
• Kawakami F, Yabata T, Ohta E, et al. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One. 2012;7(1):e30834. doi:10.1371/journal.pone.003083422303461
   PubMed Web of Science ®Google Scholar
• Ohi K, Hashimoto R, Yasuda Y, et al. The AKT1 gene is associated with attention and brain morphology in schizophrenia. World J Biol Psychiatry. 2013;14(2):100–113. doi:10.3109/15622975.2011.59182622150081
   PubMed Web of Science ®Google Scholar
• Loke H, Harley V, Lee J. Biological factors underlying sex differences in neurological disorders. Int J Biochem Cell Biol. 2015;65:139–150. doi:10.1016/j.biocel.2015.05.02426028290
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL, et al. The incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022. doi:10.1093/aje/kwg06812777365
   PubMed Web of Science ®Google Scholar
• Sham PC, MacLean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex, and familial morbidity. Acta Psychiatr Scand. 1994;89(2):135–141.8178665
   PubMed Web of Science ®Google Scholar
• Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrisons Principles of Internal Medicine. 16th ed. London: Mcgraw Hill Medical Publishing Division; 2005.
   Google Scholar
• Wilhelmus MM, Bol JG, Van Haastert ES, et al. Apolipoprotein E and LRP1 increase early in Parkinson’s disease pathogenesis. Am J Pathol. 2011;179(5):2152–2156. doi:10.1016/j.ajpath.2011.07.02121907175
   PubMed Web of Science ®Google Scholar
• Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010;1801(8):806–818. doi:10.1016/j.bbalip.2010.02.00720170744
   PubMed Web of Science ®Google Scholar
• Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. Cardiovasc Res. 2014;103(3):405–413. doi:10.1093/cvr/cvu14824907980
   PubMed Web of Science ®Google Scholar
• de Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol. 2008;3(5):505–530.19649144
   PubMed Web of Science ®Google Scholar
• Iwai A. Properties of NACP/α-synuclein and its role in Alzheimer’s disease. Biochim Biophys Acta. 2000;1502(1):95–109.10899435
   PubMed Web of Science ®Google Scholar
• Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC. Expression of alpha(2)-macroglobulin receptor/low-density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res. 2000;60(3):401–411. doi:10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.0.CO;2-L10797543
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bae EJ, Lee SJ. Extracellular α–synuclein-a novel and the crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10(2):92–98. doi:10.1038/nrneurol.2013.27524468877
   PubMed Web of Science ®Google Scholar
• Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha-synuclein oligomers. Mol Neurodegener. 2012;24:7–42.
   Google Scholar
• Dzamko N, Gysbers A, Perera G, et al. Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to α-synuclein pathology. Acta Neuropathological. 2017;133(2):303–319. doi:10.1007/s00401-016-1648-8
   Web of Science ®Google Scholar
• Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110(33):E3138. doi:10.1073/pnas.130144011023898162
   PubMed Web of Science ®Google Scholar
• Fantini J, Carlus D, Yahi N. The fusogenic tilted peptide (67–78) of α-synuclein is a cholesterol binding domain. Biochim Biophys Acta. 2011;1808(10):2343–2351. doi:10.1016/j.bbamem.2011.06.01721756873
   PubMed Web of Science ®Google Scholar
• Bar-On P, Crews L, Koob AO, et al. Statins reduce neuronal α-synuclein aggregation in vitro models of Parkinson’s disease. J Neurochem. 2008;105(5):1656–1667. doi:10.1111/j.1471-4159.2008.05254.x18248604
   PubMed Web of Science ®Google Scholar
• Emamzadeh FN, Allsop D. α-Synuclein interacts with lipoproteins in plasma. J Mol Neurosci. 2017b;63(2):165–172. doi:10.1007/s12031-017-0967-028887769
   PubMed Web of Science ®Google Scholar
• Emamzadeh FN. Role of apolipoproteins and α-synuclein in Parkinson’s disease. J Mol Neurosci. 2017a;62(3–4):344–355. doi:10.1007/s12031-017-0942-928695482
   PubMed Web of Science ®Google Scholar
• Gao N, Li YH, Li X, et al. Effect of α-synuclein on the promoter activity of the tyrosine hydroxylase gene. Neurosci Bull. 2007;23(1):53–57. doi:10.1007/s12264-007-0008-z17592526
   PubMedGoogle Scholar
• Kastner A, Hirsch EC, Herrero MT, Javoy-Agid F, Agid Y. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson’s and Alzheimer’s disease. J Neurochem. 1993;61(3):1024–1034.8103078
   PubMed Web of Science ®Google Scholar
• Peterson L, Ismond KP, Chapman E, Flood P. Potential benefits of the therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinson’s disease. J Immunol Res. 2014;2014:103780. doi:10.1155/2014/39412724741572
   PubMed Web of Science ®Google Scholar
• Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving the risk of Parkinson’s disease. Science. 2017;357(6354):891–898. doi:10.1126/science.aaf393428860381
   PubMed Web of Science ®Google Scholar
• Hsiao JT, Halliday GM, Kim WS. α-synuclein regulates neuronal cholesterol efflux. Molecules. 2017;19(22):10.
   Google Scholar
• Hirsch-Reinshagen V, Zhou S, Burgess BL, et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in the brain. J Biol Chem. 2004;279(39):41197–41207. doi:10.1074/jbc.M40796220015269218
   PubMed Web of Science ®Google Scholar
• Kamisuki S, Mao Q, Abu-Elheiga L, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009;16(8):882–892. doi:10.1016/j.chembiol.2009.07.00719716478
   PubMedGoogle Scholar
• Cheng D, Kim WS, Garner B. Regulation of α-synuclein expression by liver X receptor ligands in vitro. Neuroreport. 2008;19(17):1685–1689. doi:10.1097/WNR.0b013e32831578b218841091
   PubMed Web of Science ®Google Scholar
• Wheatley VR, Brind JL. Sebaceous gland differentiation: III. The uses and limitations of freshly isolated mouse preputial gland cells for the in vitro study of hormone and drug action. J Invest Dermatol. 1981;76(4):293–296.6162901
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann N YAcad Sci. 2003;991(1):120–131. doi:10.1111/j.1749-6632.2003.tb07470.x
   Google Scholar
• Bosco DA, Fowler DM, Zhang Q, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat Chem Biol. 2006;2(5):249–253. doi:10.1038/nchembio78216565714
   PubMed Web of Science ®Google Scholar
• Gallardo G, Schlüter OM, Südhof TC. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nature Neurosci. 2008;11(3):301. doi:10.1038/nn205818297066
   PubMed Web of Science ®Google Scholar
• Ruipérez V, Darios F, Davletov B. α-synuclein, lipids and Parkinson’s disease. Prog Lipid Res. 2010;49(4):420–428. doi:10.1016/j.plipres.2010.05.00420580911
   PubMed Web of Science ®Google Scholar
• Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci. 2006;103(15):5644–5651. doi:10.1073/pnas.060054910316567625
   PubMed Web of Science ®Google Scholar
• Chang S, Ran Ma T, Miranda RD, et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci. 2005;102(51):18694–18699. doi:10.1073/pnas.050825410216344479
   PubMed Web of Science ®Google Scholar